Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 77 (high attention) · dilution pressure elevated · listing risk elevated · governance risk low · runway 5.6 mo · strongest signal: MVLS deficiency (Sep 14, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 265 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 14, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (8-K) filed 2026-09-14 filing | 51 |
| Sep 14, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (8-K) filed 2026-09-14 filing | 39 |
| Dec 31, 2025 | ▼ Negative equity | Stockholders' equity $-38,062,000 as of 2025-12-31 filing | 31 |
| Dec 31, 2025 | ▼ Runway < 6 months | ~5.6 months runway: liquidity $6,175,000 as of 2025-12-31, burn $13,254,000/yr (latest fiscal-year operating cash flow [companyfacts]) filing | 28 |
| Dec 31, 2025 | ▼ Cash < current liabilities | Liquidity $6,175,000 vs current liabilities $80,759,000 filing | 22 |
DAIC CID Holdco, Inc. · SDST Stardust Power Inc. · ISPC iSpecimen Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · BRTX BioRestorative Therapies, In · screener →